Inventiva reports
Inventiva reports 2023 First Quarter Financial Information¹ and provides a corporate update
16 mai 2023 16h00 HE | INVENTIVA
Cash and cash equivalents at €56.3 million, short-term deposits at €0.7 million2, and long term deposit at €9.3 million3 as of March 31, 2023, compared to €86.7 million, €1.0 million and €0.7 million...
Infant Bacterial The
Infant Bacterial Therapeutics AB (publ), Delårsrapport 1 januari – 31 mars 2023
08 mai 2023 07h00 HE | Infant Bacterial Therapeutics AB
VD kommenterar Under de senaste månaderna har det skett betydelsefulla framsteg inom utvecklingen av mikrobiom-läkemedel. Ferrings/Rebiotics produkt REBYOTA™ godkändes av FDA i slutet av förra året...
Infant Bacterial The
Infant Bacterial Therapeutics AB (publ), Interim report January 1-March 31, 2023
08 mai 2023 07h00 HE | Infant Bacterial Therapeutics AB
 Message from the CEO Significant advancements have been made in the development of microbiome-based pharmaceuticals in the past few months. Ferring/Rebiotics' product REBYOTA™ was approved by the...
New CSX_BLUE_RGB_JPG.jpg
CSX Corp. Announces Date for First Quarter Earnings Release and Earnings Call
23 mars 2023 10h00 HE | CSX Corporation
JACKSONVILLE, Fla., March 23, 2023 (GLOBE NEWSWIRE) -- CSX Corp. (NASDAQ: CSX) will release first quarter financial and operating results after the market close on Thursday, April 20, 2023. This...
Infant Bacterial The
Infant Bacterial Therapeutics publicerar årsredovisning för 2022
22 mars 2023 16h30 HE | Infant Bacterial Therapeutics AB
Infant Bacterial Therapeutics AB (publ) publicerar idag årsredovisningen för räkenskapsåret 2022. Årsredovisningen finns tillgänglig på IBTs hemsida, www.ibtherapeutics.com under avsnittet...
Infant Bacterial The
Infant Bacterial Therapeutics publishes Annual Report for 2022
22 mars 2023 16h30 HE | Infant Bacterial Therapeutics AB
Infant Bacterial Therapeutics AB (publ) publishes today the Annual Report for 2022. The report is available on IBT´s website, ibtherapeutics.com under the section Ïnvestors & Media – Financial...
Pieridae logo_Hunter.jpg
Pieridae Releases Q4 and Full Year 2022 Results, 2022 Reserves & Revises 2023 Guidance
22 mars 2023 07h30 HE | Pieridae Energy Limited
NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES ORDISSEMINATION IN UNITED STATES CALGARY, Alberta, March 22, 2023 (GLOBE NEWSWIRE) -- Pieridae Energy Limited (“Pieridae” or the “Company”)...
Correction: Inventiv
Correction: Inventiva publie ses résultats financiers préliminaires pour l’exercice 2022¹
14 févr. 2023 17h00 HE | INVENTIVA
Daix (France), Long Island City (New York, Etats-Unis), le 14 février 2023 – Inventiva (Euronext Paris et Nasdaq : IVA) (la "Société"), société biopharmaceutique spécialisée dans le développement...
Correction: Inventiv
Correction: Inventiva reports preliminary financial results for Full-Year 2022¹
14 févr. 2023 17h00 HE | INVENTIVA
Daix (France), Long Island City (New York, United States), February 14, 2023 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a clinical-stage biopharmaceutical company focused on the...
Inventiva reports pr
Inventiva reports preliminary financial results for Full-Year 2022¹
14 févr. 2023 16h00 HE | INVENTIVA
Daix (France), Long Island City (New York, United States), February 14, 2023 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a clinical-stage biopharmaceutical company focused on the...